Pfizer Inc. (NYSE: PFE) announced today positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis (AS).
https://www.theglobeandmail.com/investing/markets/stocks/PFE-N/

